GCLLSG 2016 | The current status of CLL treatment and how clinical practice will change
John Gribben, MD, DSc, FRCPath, FMed Sci of Barts Cancer Institute, London, UK gives an overview on his talk on the current and future clinical practice of chronic lymphocytic leukemia (CLL) treatment at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Prof. Gribben explains that CLL research very rapidly becomes out of date, meaning that this field has moved on significantly over the past few years. He explains that there are a huge number of ongoing studies looking at finding right combinations of therapies. A large number of agents have just been approved and studies are trying to figure out what is the right order in which those agents must be sequenced and how they can be combined. Furthermore, there is a lot of discussion around whether the right approach would be to use agents together in combination or whether they should be sequenced individually. He explains that the consensus seems to be that sequential treatment might potentially be the right way ahead. Various studies are looking at molecular markers as well to determine who responds particularly well to one therapy versus another. Those are all currently clinical trial questions but the speed with which these new agents have come in and replaced some of the old therapies has been extremely fast.
Get great new content delivered to your inboxSign up